Japan's Takeda expects $200 mln operating loss related to Novartis' Xiidra withdrawal

This post was originally published on this site

The drug was one of the products Takeda obtained through its acquisition of Shire Plc (L:SHP) in January 2019. In July 2019, Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.

Swiss drugmaker Novartis last week withdrew an application for European approval of Xiidra after regulators concluded its effectiveness had not been demonstrated.

Add Comment